Covaxin is based on an inactivated whole SARS-CoV-2 virion. In partnership with the ICMR, the interim analysis was conducted. And so after the third round of trial, it was confirmed that Covaxin is 81% effective.
Recent Statistical Data of Covaxin
Covaxin has an efficacy of 81% according to the interim results. So, this means that compared to the group that received a placebo, nearly 81% of the vaccine was able to bring down the number of symptomatic Covid-19 cases. The study was conducted on 43 participants who had tested positive for Covid-19 two weeks after receiving their second dose and showed mild, moderate, or severe symptoms. It was a trial to check how many of these participants had received Covaxin and how many got a placebo. So, the result was that seven had received Covaxin and 36 received a placebo.
Why Covaxin is Important?
To fight against Covid-19, two vaccines were used in India’s mass vaccination program of which Covaxin is one of them. A higher efficacy would mean a higher chance of protecting the vulnerable population against the deadly virus. After the results of the third trial were announced, vaccine expert Dr. Gagandeep Kang breathed an air of relief. She said,” The interim analyses test the vaccine much more, so if it has around 81% efficacy, then that means it is likely to maintain a high level of efficacy even when the full results are released.”
TPT Policy Advocacy & Recommendations
- Bharat Biotech has a long way to go as the efficacy of the results is only based on 43 participants whereas, to inoculate a mass number of people, a trial on more than 43 participants is needed.
- Bharat Biotech also needs to find out the full potential of protection of Covaxin against infection as a safety profile is needed by the mass population.
